Video

Case Studies in Type 2 Diabetes: Which Agents and Why

Publish date: October 16, 2015
Author(s):
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC
B. Scott Urquhart, PA-C, DFAAPA
Author and Disclosure Information

 

References

Lucia M. Novak and B. Scott Urquhart describe the parameters for glucose lowering, using glucose- and patient-centric approaches for achieving the target A1C. This video provides three takeaways in less than three minutes from their presentation at the 2015 MEDS conference, which

  1. Reviewed the current ADA/EASD, and AACE guidelines for pharmacologic management of diabetes.
  2. Critiqued the pharmacologic options with their expected A1c reductions, side effect profiles and safety concerns.
  3. Applied a glucose-centric approach to incorporate oral and non-insulin injectable agents in the treatment of patients with type 2 diabetes.
  4. Demonstrated how a patient-centric approach promotes empowerment and positive outcomes.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Explore intriguing new cases in type 2 diabetes with endocrine experts Lucia Novak and Scott Urquhart at the upcoming 2016 MEDS conference. Click here to learn more.

Recommended Reading

Prediabetes and Metabolic Syndrome: Current Trend
Clinician Reviews
Liraglutide/metformin Targets Glycemic Goal in Type 2 Diabetes
Clinician Reviews
Long-acting Basal Insulin Controls A1C as Well as Glargine
Clinician Reviews
When Stepping up Type 2 Treatment, GLP-1 Agonists Have the Edge
Clinician Reviews
Lipid-lowering Benefits of Alirocumab Extend to Patients With High-risk Diabetes
Clinician Reviews
Metformin-induced B12 Deficiency Linked to Diabetic Neuropathy
Clinician Reviews
GLP-1 Receptor Agonists in Your Toolkit
Clinician Reviews
Type 2 Diabetes in the Pediatric Patient
Clinician Reviews
Monthly Incretin-based Therapy Shows Promise in Type 2 Diabetes
Clinician Reviews
Progress in Treating Diabetic Foot Osteomyelitis
Clinician Reviews